New drug aims to outperform current therapy in Hard-to-Treat breast cancer
NCT ID NCT07678957
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This study compares a new experimental drug, BL-M07D1, to an approved therapy (DS-8201) in people with a common form of advanced breast cancer (HR-positive, HER2-low). The goal is to see if the new drug can delay cancer growth or improve survival. About 120 women aged 18 to 75 with recurrent or metastatic disease will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BL-M07D1
What this could lead to
If BL-M07D1 works better than DS-8201, it could offer a new treatment option for people with this type of breast cancer.
What could go wrong
This is an early-phase trial with only 120 participants, so results may not apply to everyone. The new drug could have unexpected side effects or not improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Contact